Leapfrog Bio

1 known investors

Leapfrog develops precision cancer therapies by using its OncoSLX platform to identify genetic vulnerabilities in cancers driven by loss-of-function mutations and repurposing clinical-stage drugs against them. Its lead candidate, LFB190, is a BET inhibitor targeting EP300 loss-of-function mutant cancers, with additional programs including PIK3CA mutant cancers.